Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - roflumilast - mard tal-pulmun, obstructive kronika - mediċini għall-imblokkar tal-passaġġ tan-nifs mard, - daliresp huwa indikat għall-manutenzjoni trattament severi kronika eliminat pulmonari marda (copd) (fev1 bronchodilator wara inqas minn 50% mbassra) assoċjati ma ' bronchitis kroniċi fil-pazjenti adulti bi storja ta ' spiss exacerbations bħala żieda trattament bronchodilator.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

gentium s.r.l. - defibrotide - mard epatiku-okklussiv tal-vini - aġenti antitrombotiċi - defitelio huwa indikat għall-kura ta ' severi epatiċi okklussivi veno marda (vod) magħrufa wkoll bħala sinusojdali eliminat syndrome (sos) f'terapija haematopoietic-ċelloli staminali trapjant (hsct). huwa indikat fl-adulti u fl-adoloxxenti, tfal u trabi ' l fuq minn 1 xahar ta'età.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propanediol monohydrate - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogi użati fid-dijabete - type 2 diabetes mellitusedistride is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. barra minn hekk għall-prodotti mediċinali oħra għat-trattament tad-dijabete tat-tip 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 u 5. heart failureedistride is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseedistride is indicated in adults for the treatment of chronic kidney disease.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

gilead sciences ireland uc - sofosbuvir, velpatasvir - epatite Ċ, kronika - antivirali għal użu sistemiku - epclusa is indicated for the treatment of chronic hepatitis c virus (hcv) infection in patients 3 years of age and older (see sections 4. 2, 4. 4 u 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

instituto grifols s.a. - l-immunoglobulina normali umana - mucocutaneous lymph node syndrome; guillain-barre syndrome; bone marrow transplantation; purpura, thrombocytopenic, idiopathic; immunologic deficiency syndromes - sera immuni u immunoglobulini, - replacement therapy in adults, children and adolescents (0-18 years) in: , primary immunodeficiency syndromes with impaired antibody production;, hypogammaglobulinaemia and recurrent bacterial infections in patients with chronic lymphocytic luekaemia, in whom prophylactic antibiotics have failed;, hypogammaglobulinaemia and recurrent bacterial infections in plateau-phase-multiple-myeloma patients who failed to respond to pneumococcal immunisation;, hypogammaglobulinaemia in patients after allogenic haematopoietic-stem-cell transplantation (hsct);, congenital aids with recurrent bacterial infections. , immunomodulation in adults, children and adolescents (0-18 years) in: , primary immune thrombocytopenia (itp), in patients at high risk of bleeding or prior to surgery to correct the platelet count;, guillain barré syndrome;, kawasaki disease.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

astrazeneca ab - dapagliflozin propanediol monohydrate - diabetes mellitus, type 2; heart failure, systolic; heart failure; renal insufficiency, chronic - drogi użati fid-dijabete - type 2 diabetes mellitusforxiga is indicated in adults and children aged 10 years and above for the treatment of insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exerciseas monotherapy when metformin is considered inappropriate due to intolerance. barra minn hekk għall-prodotti mediċinali oħra għat-trattament tad-dijabete tat-tip 2. for study results with respect to combination of therapies, effects on glycaemic control, cardiovascular and renal events, and the populations studied, see sections 4. 4, 4. 5 u 5. heart failureforxiga is indicated in adults for the treatment of symptomatic chronic heart failure. chronic kidney diseaseforxiga is indicated in adults for the treatment of chronic kidney disease.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

gilead sciences ireland uc - ledipasvir, sofosbuvir - epatite Ċ, kronika - antivirali għal użu sistemiku - harvoni is indicated for the treatment of chronic hepatitis c (chc) in adult and paediatric patients aged 3 years and above (see sections 4. 2, 4. 4 u 5. għall-vajrus tal-epatite Ċ (hcv) ġenotip-attività speċifika ara sezzjonijiet 4. 4 u 5.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

intervet international bv - razez tal-virus ta 'l-influwenza taż-żwiemel: a / equine-2 / afrika t'isfel / 4/03, a / equine-2 / newmarket / 2/93 - virus tal-influwenza ekwina - Żwiemel - immunizzazzjoni attiva ta 'żwiemel minn sitt xhur ta' età kontra l-influwenza taż-żwiemel biex jitnaqqsu s-sinjali kliniċi u l-eskrezzjoni tal-virus wara l-infezzjoni.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

intervet international bv - razez tal-virus tal-influwenza ekwina: a / equine-2 / afrika t'isfel / 4/03, a / equine-2 / newmarket / 2/93, toxoid tat-tetnu - virus tal-influwenza ekwina + clostridium - Żwiemel - immunizzazzjoni attiva ta 'żwiemel minn sitt xhur ta' età kontra l-influwenza taż-żwiemel biex tnaqqas is-sinjali kliniċi u l-eskrezzjoni tal-virus wara l-infezzjoni, u immunizzazzjoni attiva kontra t-tetnu biex tevita l-mortalità.

Unjoni Ewropea - Malti - EMA (European Medicines Agency)

intervet international bv - toxoid tat-tetnu - immunoloġiċi għall-equidae - Żwiemel - immunizzazzjoni attiva ta 'żwiemel li għandhom età ta' 6 xhur kontra t-tetnu biex tevita l-mortalità. bidu ta 'immunità: 2 ġimgħat wara l-vaċċinazzjoni primarja courseduration ta' l-immunità: 17-il xahar wara l-ewwel kors ta ' tilqim, 24 xahar wara l-ewwel revaċċinazzjoni.